| [February 27, 2017] |
 |
Global Bacterial Partnering Deals and Agreements Between the World's Leading Pharmaceutical and Biotechnology Companies 2010-2017 - Research and Markets
Research and Markets has announced the addition of the "Global
Bacterial Partnering 2010-2017: Deal trends, players and financials"
report to their offering.
Global Bacterial Partnering 2010 to 2017 provides the full collection of
Bacterial disease deals signed between the world's pharmaceutical and
biotechnology companies since 2010.
Most of the deals included within the report occur when a licensee
obtains a right or an option right to license a licensor's product or
technology. More often these days these deals tend to be multi-component
including both a collaborative R&D and a commercialization of outcomes
element.
The report takes readers through the comprehensive Bacterial disease
deal trends, key players and top deal values allowing the understanding
of how, why and under what terms companies are currently entering
Bacterial deals.
The report presents financial deal terms values for Bacterial deals,
where available listing by overall headline values, upfront payments,
milestones and royalties enabling readers to analyse and benchmark the
value of current deals.
Report scope:
-
Trends in Bacterial dealmaking in the biopharma industry since 2010
-
Analysis o Bacterial deal structure
-
Access to headline, upfront, milestone and royalty data
-
Access to hundreds of Bacterial deal contract documents
-
Comprehensive access to over 3500 Bacterial deal records
-
The leading Bacterial deals by value since 2010
-
Most active Bacterial dealmakers since 2010
The report includes deals for the following indications:
-
Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile,
Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B
Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter
Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus
(MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas
aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other
bacterial indications
Analyzing actual contract agreements allows assessment of the
following:
-
What are the precise bacterial rights granted or optioned?
-
What is actually granted by the agreement to the partner company?
-
What exclusivity is granted?
-
What is the payment structure for the deal?
-
How aresalesand payments audited?
-
What is the deal term?
-
How are the key terms of the agreement defined?
-
How are IPRs handled and owned?
-
Who is responsible for commercialization?
-
Who is responsible for development, supply, and manufacture?
-
How is confidentiality and publication managed?
-
How are disputes to be resolved?
-
Under what conditions can the deal be terminated?
-
What happens when there is a change of ownership?
-
What sublicensing and subcontracting provisions have been agreed?
-
Which boilerplate clauses does the company insist upon?
-
Which boilerplate clauses appear to differ from partner to partner or
deal type to deal type?
-
Which jurisdiction does the company insist upon for agreement law?
For more information about this report visit http://www.researchandmarkets.com/research/jsn269/global_bacterial
View source version on businesswire.com: http://www.businesswire.com/news/home/20170227005714/en/
[ Back To TMCnet.com's Homepage ]
|
